(4E,13Z)-2-amino-3-oxoicosa-4,13-dienoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: (4E,13Z)-2-amino-3-oxoicosa-4,13-dienoic acid
• 化学式: C₂₀H₃₅NO₃
• 分子量: 337.5
• InChiKey: QCQNRPMBJGNQAA-MDTHSCKASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  16
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.7
• 拓扑面积：
  80.4
• 氢给体数：
  2
• 氢受体数：
  4

文献信息

• PHARMACEUTICAL COMPOSITIONS
  申请人：Rhythm Pharmaceuticals, Inc.

  公开号：EP2970389B1

  公开（公告）日：2020-08-19
• [EN] PHARMACEUTICAL COMPOSITIONS<br/>[FR] COMPOSITIONS PHARMACEUTIQUES
  申请人：RHYTHM METABOLIC INC

  公开号：WO2014144842A2

  公开（公告）日：2014-09-18

  The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the the ionic complex and pharmaceuctical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.